TAK1-inhibitors are cytotoxic for multiple myeloma cells alone and in combination with melphalan.

Autor: Håland E; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Moen IN; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway., Veidal E; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Hella H; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Misund K; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway., Slørdahl TS; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway., Starheim KK; CEMIR Centre of Molecular Inflammation Research, IKOM, NTNU, Trondheim, Norway.; Department of Clinical and Molecular Medicine, NTNU, Trondheim, Norway.; Department of Hematology, St. Olavs University Hospital, Trondheim, Norway.

Publikováno v: Oncotarget [Oncotarget] 2021 Oct 12; Vol. 12 (21), pp. 2158-2168. Date of Electronic Publication: 2021 Oct 12 (Print Publication: 2021).

The TLR4 adaptor TRAM controls the phagocytosis of Gram-negative bacteria by interacting with the Rab11-family interacting protein 2.

Autor: Skjesol A; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Yurchenko M; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Bösl K; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Gravastrand C; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Nilsen KE; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Grøvdal LM; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Agliano F; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Patane F; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Lentini G; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Kim H; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Teti G; Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy., Kumar Sharma A; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Kandasamy RK; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Sporsheim B; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Starheim KK; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway., Golenbock DT; Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, United States of America., Stenmark H; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; Centre for Cancer Cell Reprogramming, Faculty of Medicine, University of Oslo, Oslo, Norway.; Department for Molecular Cell Biology, Institute for Cancer Research, Oslo University Hospital, Oslo Norway., McCaffrey M; Molecular Cell Biology Laboratory, Biochemistry Department, Biosciences Institute, University College Cork, Cork, Ireland., Espevik T; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; The Central Norway Regional Health Authority, St. Olavs Hospital HF, Trondheim, Norway., Husebye H; Centre of Molecular Inflammation Research, Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.; The Central Norway Regional Health Authority, St. Olavs Hospital HF, Trondheim, Norway.

Publikováno v: PLoS pathogens [PLoS Pathog] 2019 Mar 18; Vol. 15 (3), pp. e1007684. Date of Electronic Publication: 2019 Mar 18 (Print Publication: 2019).

A Role for Human N-alpha Acetyltransferase 30 (Naa30) in Maintaining Mitochondrial Integrity.

Autor: Van Damme P; From the ‡Medical Biotechnology Center, VIB, B-9000 Ghent, Belgium; petra.vandamme@vib-ugent.be.; §Department of Biochemistry, Ghent University, B-9000 Ghent, Belgium., Kalvik TV; ¶Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway., Starheim KK; ¶Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway.; ‖Department of Clinical Science, University of Bergen, N-5020 Bergen, Norway.; *Center of Molecular Inflammation Research, Department of Molecular Medicine and Cancer Research, Norwegian University of Technology and Natural Sciences, N-7006 Trondheim, Norway., Jonckheere V; From the ‡Medical Biotechnology Center, VIB, B-9000 Ghent, Belgium.; §Department of Biochemistry, Ghent University, B-9000 Ghent, Belgium., Myklebust LM; ¶Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway., Menschaert G; ‡‡Department of Mathematical Modeling, Statistics and Bioinformatics, Ghent University, B-9000 Ghent, Belgium., Varhaug JE; ‖Department of Clinical Science, University of Bergen, N-5020 Bergen, Norway.; §§Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway., Gevaert K; From the ‡Medical Biotechnology Center, VIB, B-9000 Ghent, Belgium.; §Department of Biochemistry, Ghent University, B-9000 Ghent, Belgium., Arnesen T; ¶Department of Molecular Biology, University of Bergen, N-5020 Bergen, Norway.; §§Department of Surgery, Haukeland University Hospital, N-5021 Bergen, Norway.

Publikováno v: Molecular & cellular proteomics : MCP [Mol Cell Proteomics] 2016 Nov; Vol. 15 (11), pp. 3361-3372. Date of Electronic Publication: 2016 Sep 30.

Manipulation of interleukin-1β and interleukin-18 production by Yersinia pestis effectors YopJ and YopM and redundant impact on virulence.

Autor: Ratner D, Orning MP, Starheim KK, Marty-Roix R, Proulx MK, Goguen JD, Lien E

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2016 Jul 29; Vol. 291 (31), pp. 16417.

Manipulation of Interleukin-1β and Interleukin-18 Production by Yersinia pestis Effectors YopJ and YopM and Redundant Impact on Virulence.

Autor: Ratner D; From the Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605., Orning MP; From the Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, the Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway, and., Starheim KK; From the Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, the Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway, and., Marty-Roix R; From the Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605., Proulx MK; the Department of Microbiology and Physiological Systems, University of Massachusetts, Worcester, Massachusetts 01655., Goguen JD; the Department of Microbiology and Physiological Systems, University of Massachusetts, Worcester, Massachusetts 01655., Lien E; From the Program in Innate Immunity, Division of Infectious Diseases and Immunology, Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605, the Centre of Molecular Inflammation Research, Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, 7491 Trondheim, Norway, and egil.lien@umassmed.edu.

Publikováno v: The Journal of biological chemistry [J Biol Chem] 2016 May 06; Vol. 291 (19), pp. 9894-905. Date of Electronic Publication: 2016 Feb 16.